Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

被引：96
|
作者：
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 01期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN; LYMPHOMA; PCI-32765; ACTIVATION; REGRESSION; INDICATE; SURVIVAL; BIOLOGY; SETS;
D O I：
10.1200/JCO.2012.44.4281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：128 / 130
页数：3
相关论文
共 50 条
  • [1] Targeting Bruton's Tyrosine Kinase With Ibrutinib in B-Cell Malignancies
    Wang, Y.
    Zhang, L. L.
    Champlin, R. E.
    Wang, M. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (05) : 455 - 468
  • [2] Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
    Caspar da Cunha-Bang
    Carsten Utoft Niemann
    Drugs, 2018, 78 : 1653 - 1663
  • [3] Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies
    da Cunha-Bang, Caspar
    Niemann, Carsten Utoft
    DRUGS, 2018, 78 (16) : 1653 - 1663
  • [4] Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies
    Marostica, Eleonora
    Sukbuntherng, Juthamas
    Loury, David
    Jong, Jan D.
    de Trixhie, Xavier Woot
    Vermeulen, An
    de Nicolao, Giuseppe
    O'Brien, Susan
    Byrd, John C.
    Advani, Ranjana
    McGreivy, Jesse
    Poggesi, Italo
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
    Huynh, Tiana
    Rodriguez-Rodriguez, Sonia
    Danilov, Alexey V.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (05) : 619 - 626
  • [6] Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies (Review)
    Xia, Bing
    Qu, Fulian
    Yuan, Tian
    Zhang, Yizhuo
    ONCOLOGY LETTERS, 2015, 10 (06) : 3339 - 3344
  • [7] Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
    Gayko, Urte
    Fung, Mann
    Clow, Fong
    Sun, Steven
    Faust, Elizabeth
    Price, Samiyeh
    James, Danelle
    Doyle, Margaret
    Bari, Samina
    Zhuang, Sen Hong
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 82 - 94
  • [8] Functional role of Bruton′s tyrosine kinase inhibitor therapy in the tumor microenvironment of B-cell malignancies
    Barbarino, V.
    Henschke, S.
    Blakemore, S. J.
    Nickel, N.
    Vorholt, D.
    Hallek, M.
    Pallasch, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 220 - 221
  • [9] Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
    Abbas, Hussein A.
    Wierda, William G.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
    Aalipour, Amin
    Advani, Ranjana H.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (04) : 121 - 133
12345